374 related articles for article (PubMed ID: 34557415)
1. The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Xu Y; Wang Q; Xie J; Chen M; Liu H; Zhan P; Lv T; Song Y
Front Oncol; 2021; 11():732214. PubMed ID: 34557415
[TBL] [Abstract][Full Text] [Related]
2. Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis.
Xia H; Zhang W; Zhang Y; Shang X; Liu Y; Wang X
Front Oncol; 2022; 12():978069. PubMed ID: 36330494
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
[TBL] [Abstract][Full Text] [Related]
4. The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.
Chu X; Niu L; Xiao G; Peng H; Deng F; Liu Z; Wu H; Yang L; Tan Z; Li Z; Zhou R
Front Immunol; 2022; 13():875488. PubMed ID: 35693805
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis.
Alifu M; Tao M; Chen X; Chen J; Tang K; Tang Y
Front Oncol; 2023; 13():1146905. PubMed ID: 37397392
[TBL] [Abstract][Full Text] [Related]
6. Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis.
Li F; Zhai S; Lv Z; Yuan L; Wang S; Jin D; Yi H; Fu L; Mao Y
Front Oncol; 2022; 12():968517. PubMed ID: 36439448
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than
Tian T; Li Y; Li J; Xu H; Fan H; Zhu J; Wang Y; Peng F; Gong Y; Du Y; Yan X; He X; Cali Daylan AE; Pircher A; Neibart SS; Okuma Y; Hong MH; Huang M; Lu Y
Transl Lung Cancer Res; 2024 Apr; 13(4):861-874. PubMed ID: 38736501
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics.
Liu W; Huo G; Chen P
BMC Cancer; 2023 May; 23(1):458. PubMed ID: 37202730
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features.
Huo G; Liu W; Chen P
Front Immunol; 2022; 13():875093. PubMed ID: 35479081
[TBL] [Abstract][Full Text] [Related]
11. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
[No Abstract] [Full Text] [Related]
12. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
Front Oncol; 2022; 12():753234. PubMed ID: 35280736
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis.
Yang K; Li J; Bai C; Sun Z; Zhao L
Front Oncol; 2020; 10():1098. PubMed ID: 32733805
[No Abstract] [Full Text] [Related]
14. Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis.
Sheng L; Gao J; Xu Q; Zhang X; Huang M; Dai X; Li S; Liu L
Ther Adv Med Oncol; 2021; 13():17588359211018537. PubMed ID: 34104227
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis.
Qian X; Guo X; Li T; Hu W; Zhang L; Wu C; Ye F
Front Pharmacol; 2022; 13():926890. PubMed ID: 36071838
[No Abstract] [Full Text] [Related]
16. The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis.
Dai L; Jin B; Liu T; Chen J; Li G; Dang J
EClinicalMedicine; 2021 Aug; 38():100990. PubMed ID: 34505024
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis.
Liu W; Huo G; Chen P
Front Immunol; 2022; 13():909027. PubMed ID: 35799785
[TBL] [Abstract][Full Text] [Related]
18. The influence of baseline characteristics on the efficacy of immune checkpoint inhibitors for advanced lung cancer: A systematic review and meta-analysis.
Xiao Q; Yu X; Shuai Z; Yao T; Yang X; Zhang Y
Front Pharmacol; 2022; 13():956788. PubMed ID: 36176428
[No Abstract] [Full Text] [Related]
19. First-line immunotherapy efficacy in advanced squamous non-small cell lung cancer with PD-L1 expression ≥50%: a network meta-analysis of randomized controlled trials.
Chen W; Liu H; Li Y; Xue W; Fan S; Sun J; Liu S; Liu Y; Zhang L
Front Oncol; 2024; 14():1365255. PubMed ID: 38725635
[TBL] [Abstract][Full Text] [Related]
20. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
